PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country. Read More
HONG KONG – A new anticorruption law in South Korea, known as the “Kim Young-ran Act,” could have a significant and long-term impact on pharmaceutical companies, even if its focus is much wider than any one industry. Read More
SHANGHAI – It’s not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that’s exactly what Shanghai-based Zai Lab Ltd. did when it obtained exclusive China rights for niraparib from Tesaro Inc., of Waltham, Mass. A PARP inhibitor, niraparib has shown promise in phase III ovarian cancer trials and is being evaluated in BRCA-mutant breast cancer and prostate cancer. Read More
HONG KONG – You win some and you lose some. Fresh from losing a licensing deal with German pharmaceutical giant Boehringer Ingelheim GmbH and watching its stock price plummet, South Korea’s Hanmi Pharmaceutical Co. Ltd. inked an exclusive $910 million development and licensing agreement with Genentech Inc., of South San Francisco, for the development and commercialization of its pan-RAF inhibitor, HM95573. Read More
HONG KONG — Treatment with low levels of carbon monoxide (CO) may offer a novel dual approach to treating traumatic brain injury (TBI), by promoting neurogenesis and preventing the death of pericytes, cells that play multiple roles in blood flow in the brain and the blood-brain barrier. Read More
